Jessica Katherine Rowena Boult1, Simon
Walker-Samuel1, Daniel P. Bradley2, Simon P. Robinson1
1CRUK and EPSRC Cancer Imaging Centre,
The Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey,
United Kingdom; 2Imaging Sciences Group, Millennium: The Takeda
Oncology Company, Cambridge, MA, United States
In
this study, susceptibility MRI with ultra-small paramagnetic iron oxide
(USPIO) and immunohistochemical methods were used to evaluate vascular and
hypoxic response of C6 glioma xenografts to chronic treatment with MLN0518, a
small molecule PDGFRα/β inhibitor. MLN0518 chronically limits the
growth of C6 xenografts and reduces both the mean perfused vessel fraction
and hypoxic area. No significant alteration in VSI, fractional blood volume
or ADC were observed by MRI following 10 days treatment. These results are
consistent with histological vessel measurements and quantification of
necrosis, neither of which altered at this timepoint.